mTOR, cancer and transplantation

American Journal of Transplantation

Volumn 8, Issue 11, 2008, Pages 2212-2218

  Geissler, Edward K ^a   Schlitt, Hans J ^a   Thomas, George ^b  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Cancer; Immunosuppression; Intracellular signalling; Transplantation

Indexed keywords

AP 23573; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; RAPAMYCIN; TACROLIMUS; TEMSIROLIMUS;

COMPLEX FORMATION; DRUG INHIBITION; DRUG RECEPTOR BINDING; ENZYME INHIBITION; GENE CONTROL; GRAFT RECIPIENT; HUMAN; IMMUNE RESPONSE; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SHORT SURVEY; SIGNAL TRANSDUCTION;

ANIMALS; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GRAFT REJECTION; HUMANS; INTERLEUKIN-2; MODELS, BIOLOGICAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; ORGAN TRANSPLANTATION; PROTEIN KINASES; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TRANSCRIPTION FACTORS;

EID: 53749101792     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2008.02391.x     Document Type: Short Survey

References (35)

1. Dann SG, Selvaraj A, Thomas G. mTOR Complex1-S6K1 signaling: At the crossroads of obesity, diabetes and cancer. Trends Mol Med 2007 13 : 252 259.
2. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006 124 : 471 484.
3. Plas DR, Thompson CB. AKT-dependent transformation: There is more to growth than just surviving. Oncogene 2005 24 : 7435 7442.
4. Lee DF, Kuo HP, Chen CT et al. IKKβ suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 2007 130 : 440 455.
5. Kim JE, Chen J. Regulation of peroxisome proliferator-activated receptor-γ activity by mammalian target of rapamycin and amino acids in adipogenesis. Diabetes 2004 53 : 2748 2756.
6. Zhang H, Bajraszewski N, Wu E et al. PDGFRs are critical for PI3K/AKT activation and negatively regulated by mTOR. J Clin Invest 2007 117 : 730 738.
7. Bai X, Ma D, Liu A et al. Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38. Science 2007 318 : 977 980.
8. 473 kinase for AKT/protein kinase B in 3T3-L1 adipocytes. J Biol Chem 2005 280 : 40406 40416.
9. Sarbassov DD, Ali SM, Sengupta S et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and AKT/PKB. Mol Cell 2006 22 : 159 168.
10. Hietakangas V, Cohen SM. Re-evaluating AKT regulation: Role of TOR complex 2 in tissue growth. Genes Dev 2007 21 : 632 637.
11. Horie Y, Suzuki A, Kataoka E et al. Hepatocyte-specific PTEN deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest 2004 113 : 1774 1783.
12. Teresi RE, Zbuk KM, Pezzolesi MG, Waite KA, Eng C. Cowden syndrome-affected patients with PTEN promoter mutations demonstrate abnormal protein translation. Am J Hum Genet 2007 81 : 756 767.
13. Hernando E, Charytonowicz E, Dudas ME et al. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med 2007 13 : 748 753.
14. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007 12 : 9 22.
15. Phung TL, Ziv K, Dabydeen D et al. Pathological angiogenesis is induced by sustained AKT signaling and inhibited by rapamycin. Cancer Cell 2006 10 : 159 170.
16. Thomas GV, Tran C, Mellinghoff IK et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006 12 : 122 127.
17. Guba M, von Breitenbuch P, Steinbauer M et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med 2002 8 : 128 135.
18. Burger RA. Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol 2007 25 : 2902 2908.
19. Reinders ME, Rabelink TJ, Briscoe DM. Angiogenesis and endothelial cell repair in renal disease and allograft rejection. J Am Soc Nephrol 2006 17 : 932 942.
20. Stallone G, Schena A, Infante B et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005 352 : 1317 1323.
21. Awada A, Cardoso F, Fontaine C et al. The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: Results of a phase I study with pharmacokinetics. Eur J Cancer 2008 44 : 84 91.
22. Chan S, Scheulen ME, Johnston S et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005 23 : 5314 5322.
23. Galanis E, Buckner JC, Maurer MJ et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group Study. J Clin Oncol 2005 23 : 5294 5304.
24. Mita MM, Mita AC, Chu QS et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol 2008 26 : 361 367.
25. Milton DT, Riely GJ, Azzoli CG et al. Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. Cancer 2007 110 : 599 605.
26. Bissler JJ, McCormack FX, Young LR et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008 358 : 140 151.
27. Sodhi A, Chaisuparat R, Hu J et al. The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. Cancer Cell 2006 10 : 133 143.
28. Shillingford JM, Murcia NS, Larson CH et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci USA 2006 103 : 5466 5471.
29. + T regulatory cells and promote organ transplant tolerance. J Immunol 2007 178 : 7018 7031.
30. + T cells. Blood 2008 111 : 453 462.
31. + regulatory T cells. J Immunol 2007 178 : 280 290.
32. + cells. J Exp Med 2008 205 : 565 574.
33. Colombo MP, Piconese S. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer 2007 7 : 880 887.
34. Zuo T, Liu R, Zhang H et al. FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2. J Clin Invest 2007 117 : 3765 3773.
35. Paik JH, Kollipara R, Chu G et al. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell 2007 128 : 309 323.